Podium to Practice: GI Cancers Symposium 2026 – BREAKWATER FOLFIRI COHORT

Podium to Practice: GI Cancers Symposium 2026 – BREAKWATER FOLFIRI COHORT

Podium to Practice: GI Cancers Symposium 2026
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Scott Berry

Icon Chair Speaker

Panelists

Dr. Sharlene Gill

Dr. Marc Peeters

Studies / Trials Discussed

13 – BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Studies/trials discussed:

13 – BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Tagged